Why Novavax Shares Are Plunging Today Despite Much Awaited FDA Emergency Nod?
The European Medicines Agency identified severe allergic reactions as potential side effects of Novavax Inc’s (NASDAQ:NVAX) COVID-19 vaccine. A few cases of…
Summit Therapeutics Mulls Additional Trial For Its Once Failed Infection Candidate
Summit Therapeutics Inc (NASDAQ:SMMT) provided an update on the clinical development of ridinilazole, its lead Phase 3 product candidate for Clostridioides…
Clene’s CNM-Au8 Shows Decreased Mortality Amyotrophic Lateral Sclerosis Patients
Clene Inc (NASDAQ:CLNN) reported significantly improved survival in Amyotrophic lateral sclerosis (ALS) patients initially treated with CNM-Au8 compared to initially randomized…
Barclays Plans To Enter This Lucrative $4.3 Trillion Asset Management Market: Report
Barclays Plc (NYSE:BCS) is seeking a Chinese banking partner to set up an asset management joint venture in the…
Despite Inflationary Pressures, Taiwan Semiconductor Records 76% Jump In Q2 Profits
Taiwan Semiconductor Manufacturing Co Ltd (NYSE: TSM) said its second-quarter profit surged over 76% to NT$237.03 billion (
Regeneron-Sanofi’s Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Phase 3 trial of Dupixent (dupilumab) in children aged 1 to 11 years…
Read Why Did Credit Suisse Raise Price Target On Kura Oncology
Credit Suisse has raised the price target on Kura Oncology Inc (NASDAQ:KURA) to $29 from $27. The analysts say that evidence of an…
Raymond James Cuts Price Target On AngioDynamics
Raymond James lowered the price target on AngioDynamics Inc (NASDAQ:ANGO) to $27 from $32 based on a 3.0x…
HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study – What’s Next
HC Wainwright downgraded Humanigen Inc (NASDAQ:HGEN) to Neutral from Buy and removed the price target based on the removal of COVID-19…
Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings
BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination.